Beta Bionics (NASDAQ:BBNX) Insider Steven Jon Russell Sells 1,026 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Steven Jon Russell sold 1,026 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $12.36, for a total transaction of $12,681.36. Following the sale, the insider directly owned 179,096 shares in the company, valued at approximately $2,213,626.56. The trade was a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Beta Bionics Stock Down 7.6%

Shares of Beta Bionics stock opened at $11.57 on Wednesday. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The company’s 50 day moving average is $18.74 and its 200 day moving average is $22.43. The company has a market cap of $513.48 million, a price-to-earnings ratio of -5.93 and a beta of 5.60.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. The business had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Short‑interest data appears unreliable or reporting‑error driven (entries show “0 shares”/NaN and 0.0 days to cover), so there’s no clear signal from short sellers in these reports — treat short‑interest changes as inconclusive for now.
• Negative Sentiment: Multiple insiders sold shares in early March (CFO Stephen Feider sold 1,428 shares at ~$12.36; other executives also sold small blocks), prompting the narrative of a wave of executive exits that can pressure the stock. These trades were disclosed in SEC Form 4 filings and covered in a TipRanks piece highlighting the coordinated sales. Beta Bionics Insiders Quietly Cash Out CFO Form 4
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice encouraging investors who suffered losses to contact them — this increases legal and reputational risk and can weigh on sentiment and share price until resolved. Faruqi & Faruqi Shareholder Reminder

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BBNX shares. Lake Street Capital set a $20.00 target price on shares of Beta Bionics in a research report on Wednesday, February 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Stifel Nicolaus decreased their target price on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Finally, Truist Financial reduced their price target on Beta Bionics from $37.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.20.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Beta Bionics during the first quarter valued at $95,000. Goldman Sachs Group Inc. bought a new position in shares of Beta Bionics during the 1st quarter valued at about $715,000. Woodline Partners LP purchased a new position in shares of Beta Bionics during the first quarter valued at about $1,530,000. Strs Ohio purchased a new position in shares of Beta Bionics during the first quarter valued at about $29,000. Finally, Rhumbline Advisers bought a new stake in shares of Beta Bionics in the first quarter worth about $158,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.